<DOC>
	<DOCNO>NCT00123929</DOCNO>
	<brief_summary>After core biopsy tumor obtain , patient locally advance breast cancer randomize receive 4 cycle full dose doxorubicin ( 75 mg/m2 e3w ) docetaxel ( 100 mg/m2 e3w ) . After fourth cycle , patient submit surgery ascertain pathological response . They receive opposite drug , hormone , Herceptin , radiation indicate .</brief_summary>
	<brief_title>Genetic Expression Prediction Response Neoadjuvant Docetaxel Doxorubicin Locally Advanced Breast Cancer</brief_title>
	<detailed_description>The aim study define genetic signature predict response single drug doxorubicin versus docetaxel . 250 patient include . cDNA microarrays produce genetic pattern correlate response doxorubicin docetaxel . Secondary aim prediction response mean IHC determination ( her2 , ER , PgR , Ki67 , protein TAU ) , FISH ( topoisomerase II alpha , her2 ) PCR ( topoisomerase II alpha ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Locally advanced , inoperable breast carcinoma stage II amenable breast preserving surgery ( amendment introduce november 2006 ) Signed informed consent Age &gt; 75 Cardiac disease ; LEFT &lt; 50 % Hyperbilirubinemia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>genetic signature</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>docetaxel</keyword>
</DOC>